NHS National Proprietary Pharmaceuticals – Low Molecular Weight Heparins and Fondaparinux – CM/PHR/22/5732
Period of Framework Agreement: 1 March 2026 to 29 February 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.